Shire Ltd.'s $6 Billion Bet On Drug For Hereditary Angioedema Pays Off With Stellar Phase III Data
Thursday, May 18, 2017 1:54 PM EDT
Shire Ltd. bought Dyax for $6 billion in 2015 for its new drug for hereditary angioedema. Shire CEO Flemming Ornskov says their multi-billion dollar bet paid off with stellar Phase III data for the drug, now called lanadelumab.
In this article: SHPG